Management of Dry Eye Toxicity After Treatment With <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38631608.
- Also identified by DOI 10.1016/j.prro.2024.04.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for patients with metastatic castration-resistant prostate cancer include use of radioligand therapy with 177Lu-PSMA-617. 177Lu-PSMA-617 is used to target prostate cancer cells selectively by targeting prostate specific membrane antigen (PSMA); however, PSMA is also expressed on lacrimal glands among other tissues. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 3 dry eye event with concomitant blepharitis after administration of 177Lu-PSMA-617. The patient was managed with neomycin-polymyxin-dexamethasone 3.5-10000-0.1 ophthalmic suspension, artificial tears, lubricating ointments, lid scrubs, and oral antihistamines.
Medical subject headings
- Dry Eye Syndromes
- Lutetium
- Prostatic Neoplasms, Castration-Resistant
- Heterocyclic Compounds, 1-Ring
- Dipeptides